Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Phase 2 Completed
22 enrolled 12 charts
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Phase 2 Completed
35 enrolled 7 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 2 Completed
41 enrolled 8 charts
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Phase 2 Completed
25 enrolled 8 charts
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
Phase 2 Completed
32 enrolled 14 charts
Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Phase 2 Completed
8 enrolled 5 charts
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Phase 2 Completed
68 enrolled 10 charts
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
14 enrolled 22 charts
RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
1 enrolled 1 chart
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
Phase 2 Terminated
11 enrolled 11 charts
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Completed
26 enrolled 7 charts
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Phase 2 Completed
20 enrolled 6 charts
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
Phase 2 Terminated
13 enrolled 6 charts
Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma
Phase 2 Completed
20 enrolled 11 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
Phase 2 Completed
43 enrolled 5 charts
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase 2 Terminated
3 enrolled 6 charts
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 2 Terminated
9 enrolled 5 charts
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
Phase 2 Completed
15 enrolled
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Phase 2 Completed
53 enrolled